Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)
Paper Details
Title
Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)
Published Date
Oct 1, 2019
Journal
Volume
30
Pages
v711 - v711
Notes
History